Free Trial
Daniil Gataulin

Daniil Gataulin Analyst Performance

Senior Research Analyst, Ophthalmology at Chardan Capital

Daniil Gataulin is a stock analyst at Chardan Capital in the medical sector, covering 15 publicly traded companies. Over the past year, Daniil Gataulin has issued 46 stock ratings, including buy and hold recommendations. While full access to Daniil Gataulin's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Daniil Gataulin's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
46 Last 0 Years
Buy Recommendations
91.30% 42 Buy Ratings
Companies Covered
15 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy91.3%42 ratings
Hold8.7%4 ratings
Sell0.0%0 ratings

Out of 46 total stock ratings issued by Daniil Gataulin at Chardan Capital, the majority (91.3%) have been Buy recommendations, followed by 8.7% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
15 companies

Daniil Gataulin, an analyst at Chardan Capital, currently covers 15 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
15 companies
100.0%

Daniil Gataulin of Chardan Capital specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
13 companies
86.7%
MED - DRUGS
2 companies
13.3%

About Daniil Gataulin

Dr. Daniil Gataulin is a Senior Research Analyst at Chardan covering Biotech companies with a focus on ophthalmology. Dr. Daniil Gataulin joined Chardan in the summer of 2021 as a VP, Senior Research Associate covering Biotechnology. Prior to Chardan, he held a Senior Research Associate position at Raymond James, where he covered SMID biotech companies with the focus on neurology, hematology, and gene therapy. Prior to his role at Raymond James, Dr. Gataulin studied the mechanism of DNA repair and recombination in the laboratory of Dr. Doug Bishop at the University of Chicago, where he discovered a novel role for ATP hydrolysis by a DNA repair/recombination protein. Dr. Gataulin holds a BS in Cell Molecular Biology from Grand Valley State University, Master’s degree in Biotechnology from Illinois Institute of Technology, and a PhD in Molecular Genetics and Cell Biology from the University of Chicago.
Follow on LinkedIn

Daniil Gataulin's Ratings History at Chardan Capital

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Ocugen, Inc. stock logo
OCGN
Ocugen
9/19/2025Reiterated Rating$1.40$7.00Buy
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
9/15/2025Initiated Coverage$12.81$21.00Buy
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
9/10/2025Downgrade$47.64$48.00Neutral
uniQure N.V. stock logo
QURE
uniQure
9/8/2025Reiterated Rating$17.95$35.00Buy
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
9/8/2025Reiterated Rating$9.71$52.00Buy
uniQure N.V. stock logo
QURE
uniQure
8/29/2025Reiterated Rating$16.26$35.00Buy
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
8/28/2025Reiterated Rating$1.09$3.00Neutral
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
8/15/2025Reiterated Rating$10.82$61.00Buy
Zura Bio Limited stock logo
ZURA
Zura Bio
8/15/2025Reiterated Rating$1.72$10.00Buy
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
8/15/2025Reiterated Rating$2.43$3.00Neutral
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
8/15/2025Reiterated Rating$8.33$35.00Buy
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
8/14/2025Reiterated Rating$21.77$70.00Buy
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
8/13/2025Reiterated Rating$2.58$33.00Buy
CervoMed Inc. stock logo
CRVO
CervoMed
8/11/2025Reiterated Rating$9.85$15.00Buy
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
8/8/2025Reiterated Rating$7.90$52.00Buy
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
8/8/2025Reiterated Rating$0.68$4.00Buy
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
8/7/2025Reiterated Rating$10.58$27.00Buy
Ocugen, Inc. stock logo
OCGN
Ocugen
8/4/2025Reiterated Rating$0.99$7.00Buy
uniQure N.V. stock logo
QURE
uniQure
7/29/2025Lower Price Target$13.68$35.00Buy
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
7/18/2025Downgrade$0.60Neutral
Ocugen, Inc. stock logo
OCGN
Ocugen
6/24/2025Reiterated Rating$0.98$7.00Buy
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
6/24/2025Reiterated Rating$12.76$61.00Buy
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
6/9/2025Reiterated Rating$9.61$52.00Buy
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
5/15/2025Reiterated Rating$1.88$33.00Buy
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
5/14/2025Lower Price Target$5.15$35.00Buy
Ocugen, Inc. stock logo
OCGN
Ocugen
5/12/2025Reiterated Rating$0.67$7.00Buy
Oculis Holding AG stock logo
OCS
Oculis
5/9/2025Boost Price Target$18.70$33.00Buy
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
5/8/2025Lower Price Target$0.35$4.00Buy
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
5/8/2025Lower Price Target$6.09$27.00Buy
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
4/23/2025Initiated Coverage$17.32$70.00Buy
Adverum Biotechnologies, Inc. stock logo
ADVM
Adverum Biotechnologies
4/17/2025Lower Price Target$2.98$33.00Buy
Oculis Holding AG stock logo
OCS
Oculis
4/17/2025Reiterated Rating$18.02$28.00Buy
uniQure N.V. stock logo
QURE
uniQure
4/1/2025Initiated Coverage$10.60$38.00Buy
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
4/1/2025Lower Price Target$7.43$61.00Buy
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
3/28/2025Reiterated Rating$15.45$90.00Buy
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
3/21/2025Lower Price Target$0.43$8.00Buy
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
3/20/2025Reiterated Rating$8.50$52.00Buy
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
3/14/2025Reiterated Rating$6.55$52.00Buy
Oculis Holding AG stock logo
OCS
Oculis
3/13/2025Reiterated Rating$18.84$28.00Buy
Ocugen, Inc. stock logo
OCGN
Ocugen
3/6/2025Boost Price Target$0.57$7.00Buy
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
3/6/2025Reiterated Rating$6.82$33.00Buy
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
2/26/2025Reiterated Rating$0.50$11.00Buy
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
2/24/2025Reiterated Rating$7.30$36.00Buy
Ocugen, Inc. stock logo
OCGN
Ocugen
2/13/2025Reiterated Rating$0.66$6.00Buy
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
2/6/2025Reiterated Rating$7.80$33.00Buy
Ocugen, Inc. stock logo
OCGN
Ocugen
1/23/2025Reiterated Rating$0.75$6.00Buy